Press Releases Merck KGaA

Equities

MRK

DE0006599905

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:36 23/01/2026 GMT			After hours 20:25:26
127.70 ^EUR	-0.55%		127.90	+0.16%

01-21	Merck: teams up with CEPI to make the Ebola vaccine more accessible in low-income countries
01-20	Merck CEO on US Business, Life Sciences Innovation	MT

Press Releases

01-21	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
01-20	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
01-12	Merck : FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor	PU
12-22	Merck : Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor	PU
12-16	Merck : Darmstadt, Germany, Launches ChemiSphere® App to Simplify Digital Data Access and Boost Lab Efficiency	PU
12-01	Merck : Darmstadt, Germany, Inaugurates Semiconductor Solutions Site in Taiwan to Support AI Growth	PU
11-28	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
11-25	Merck : Exchange offer / Tender offer - MERCK KGAA - XS2218405772 MerckKGaA 1,625% 09/09/2080	PU
11-24	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
11-20	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
11-20	Merck : High-Performance Computer Launched to Accelerate Research across Sectors	PU
11-17	Merck : Exchange offer / Tender offer - MERCK KGAA - XS2218405772 MerckKGaA 1,625% 09/09/2080	PU
11-13	Merck : Q3 25 Financial Statement	PU
11-13	Merck : Q3 25 Press Release	PU
11-13	Merck : Q3 25 Summary	PU
11-13	Merck : Q3 25 Quarterly Statement	PU
11-13	Merck : Q3 25 Earnings Presentation	PU
11-05	High Court Awards Notional Licence Fee Damages In Co-existence Dispute	AQ
11-04	Merck : Darmstadt, Germany Signs Long-term Renewable Energy Contract for South Korea Sites	PU
24/10/25	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
23/10/25	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
22/10/25	Merck Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO in Adults with Desmoid Tumors in the Journal of Clinical Oncology	AQ
21/10/25	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
17/10/25	Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	EQ
17/10/25	Merck : Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients With TGCT	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Merck CEO on US Business, Life Sciences Innovation

January 20, 2026 at 06:01 pm

Merck target raised after analyst change

December 19, 2025 at 03:45 pm